Many patients struggle to reach this goal despite multiple medications, diet modifications, and exercise programs
A larger prospective study is necessary to clarify such a benefit
This anabolic effect contributes to muscle hypertrophy, allowing for the development of larger and stronger muscle fibres over time (2)
Its typically given as a small subcutaneous injection (similar to insulin), in a short cycle of four to eight weeks
doi: 10.1111/imm.13784 94 Bang-BerthelsenCHHolmTLPykeCSimonsenLSkildeRPociotFet al
Type 2 diabetes mellitus (DM2) is a major problem because of its high and increasing prevalence throughout the world and the personal and financial costs associated with the disease.1 Appropriate management, including lifestyle and pharmacological measures, has been shown to reduce DM2 related mortality2 and complications.3 The aim of reducing the adverse effects of the traditional therapeutic agents, as well as the need for different treatment options for such a complex and diverse disease, has greatly stimulated the development of new drugs.4 In 2010, the Steering Committee of the Spanish Society of Diabetes (Sociedad Espaola de Diabetes [SED]) commissioned the Consensus and Clinical Guidelines Working Group (Grupo de Trabajo de Consensos y Guas Clnicas [GTCGC]) to prepare a document embodying as far as possible the available evidence and the different recommendations regarding the situation of diabetes in Spain.5 The idea was to update this document regularly according to the emerging evidence and the suggestions of the members of the SED
